Signal from the log
MOYOM Biotech
Undisclosed · China · Medtech
MOYOM Biotech fabrique Aphranel, un injectable résorbable de médecine esthétique à base de microsphères d'hydroxyapatite de calcium, dispositif de classe III en Chine et certifié MDR en Europe en mai 2026. Le fonds Cathay Consumer Co-Creation, géré par Cathay Capital, y investit un montant que le communiqué ne donne pas.
Spotted Amount read from the headline
Announced on , logged by the watch of 28 September 2026.
- Operation
- Funding round
- Stage
- Undisclosed
- Country
- China
- Sector
- Medtech
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
The investors
Led by Cathay Capital
What is missing before publishing
- No public amount. A missing amount is never estimated or inferred from a filing.
Provenance
Source prnewswire
Logged on 28 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification The fields shown come from an automatic reading of the source headline. They have not yet been checked against the press release and should not be quoted as verified.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.